'King Kong' weight loss jab offers hope to sufferers of severe snoring condition that hits up to 10 million Brits, study shows READ MORE: King Kong slimming jab gets green light to be offered on the NHS By Xantha Leatham For The Daily Mail Published: 21:25, 21 June 2024 | Updated: 21:25, 21 June 2024 e-mail View comments A drug dubbed 'the King Kong' of weight loss jabs can also tackle a severe snoring condition that causes sufferers to stop breathing in their sleep, a new study reveals. Researchers have discovered tirzepatide, sold under the brand name Mounjaro, can improve symptoms obstructive sleep apnoea, which affects up to 10 million Brits. Currently the only treatment is a lifestyle overhaul or a CPAP machine which helps maintain an open airway at night.
But tirzepatide represents a 'significant milestone' in managing the condition, say experts. Experts have discovered tirzepatide, sold under the brand name Mounjaro, can improve symptoms obstructive sleep apnoea, which affects up to 10 million Brits The drug has already proven dramatically effective in controlling type 2 diabetes and for weight loss. In trials, a third of type 2 diabetics on tirzepatide shed more than 20 per cent of their body weight after just over a year and saw their blood sugars brought in check.
The average person with obesity weighing 16.5 st (105 kg) lost 50 lb (23 kg) in 17 months. This makes the treatment twice as effective as semaglutide jabs, better known as Ozempic and Wegovy.
When early re.
